Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia
Study Details
Study Description
Brief Summary
RATIONALE: Panobinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with imatinib in treating patients with previously treated chronic phase chronic myelogenous leukemia.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
OBJECTIVES:
Primary
-
To determine the safety and tolerability of LBH589 given in combination with imatinib mesylate in CML patients who are in Major Cytogenetic Remission (MCR) with residual BCR-ABL positive cells after at least 1 year of daily imatinib mesylate treatment.
-
To determine the maximum tolerated dose (MTD) and dose-limiting toxicity of LBH589 given in combination with imatinib mesylate in CML patients.
Secondary
- To study the effect of LBH589 given in combination with imatinib mesylate on cytogenetic response status and BCR-ABL levels in CML patients in major cytogenetic remission on imatinib mesylate treatment.
Tertiary
- To study the effect of LBH589 given in combination with imatinib mesylate on residual BCR-ABL positive primitive progenitors in CML patients in major cytogenetic remission on imatinib mesylate treatment.
OUTLINE: This is dose-escalation study of panobinostat.
Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26. Patients also receive oral imatinib mesylate once daily on days 1-28. Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 month and then every 3 months for up to 1 year.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Treatment (panobinostat, imatinib mesylate) Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26. Patients also receive oral imatinib mesylate once daily on days 1-28. Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. |
Drug: imatinib mesylate
Given orally
Other Names:
Drug: panobinostat
Given orally
Other Names:
Genetic: polymerase chain reaction
Testing
Genetic: protein expression analysis
Testing
Genetic: western blotting
Testing
Other: flow cytometry
Testing
Other: laboratory biomarker analysis
Testing
Other: pharmacological study
Testing
|
Outcome Measures
Primary Outcome Measures
- Maximum tolerated dose of histone deacetylase inhibitor LBH589 in combination with imatinib mesylate [1 month]
- Safety and tolerability of histone deacetylase inhibitor LBH589 in combination with imatinib mesylate [4 months]
Secondary Outcome Measures
- Effect of treatment with histone deacetylase inhibitor LBH589 in combination with imatinib mesylate on cytogenetic response status and BCR-Abl levels [4 months]
- Effect of treatment with histone deacetylase inhibitor LBH589 in combination with imatinib mesylate on residual BCR-Abl positive primitive progenitors [4 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
-
CML CP patients who have been treated with and tolerated Imatinib for 1 year or more, have achieved at least major cytogenetic response and continue to be BCR-ABL positive (Patients should be receiving Imatinib at a dose of 400 daily at the time of entry into the study)
-
ANC and PLT need to be in the normal range
-
Serum albumin >= 3g/dL
-
AST/SGOT and ALT/SGPT =< 2.5 x upper limit of normal (ULN)
-
Serum bilirubin =< 1.5 x ULN
-
Serum creatinine =< 1.5 x ULN or 24-hour creatinine clearance >= 50 ml/min
-
Serum potassium >= lower limit of normal (LLN)
-
Serum phosphorus >= LLN
-
Serum total calcium (corrected for serum albumin) or serum ionized calcium >= LLN
-
Serum magnesium >= LLN
-
ECOG performance status of =< 2
Exclusion Criteria:
-
Prior treatment with an HDAC inhibitor
-
Patient who have been treated with Imatinib < 1 year or patients are currently being treated with Imatinib at a dose > 400 mg daily
-
Impaired cardiac function including any one of the following: Screening ECG with a QTc
450 msec; Patients with congenital long QT syndrome; History or presence of sustained ventricular tachycardia; Any history of ventricular fibrillation or torsades de pointes; Bradycardia defined as heart rate < 50 beats per minute (patients with a pacemaker and heart rate >= 50 beats per minute are eligible); Patients with a myocardial infarction or unstable angina within 6 months of study entry; Congestive heart failure (NY Heart Association class III or IV); Right bundle branch block and left anterior hemiblock (bifascicular block)
-
Uncontrolled hypertension
-
Concomitant use of drugs with a risk of prolonging the QT interval or inducing torsades de pointes
-
Concomitant use of CYP3A4 inhibitors
-
Patients with unresolved diarrhea > CTCAE grade 1
-
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589
-
Other concurrent severe and/or uncontrolled medical conditions
-
Patients who have received chemotherapy, any investigational drug or undergone major surgery < 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
-
Concomitant use of any other anti-cancer therapy or radiation therapy
-
Patients being treated with Coumadin (unless patients who require anticoagulation can be switched to a low-molecular weight or standard heparin)
-
Female patients who are pregnant or breast feeding or patients of reproductive potential not willing to use a double method of contraception including a barrier method (i.e. condom) during the study and 3 months after the end of treatment (Women of childbearing potential [WOCBP] must have a negative serum pregnancy test within 7 days of the first administration of oral LBH589)
-
Male patients whose sexual partners are WOCBP not willing to use a double method of contraception including condom during the study and 3 months after the end of treatment
-
Patients with a history of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin
-
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
-
Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | City of Hope Medical Center | Duarte | California | United States | 91010-3000 |
2 | South Pasadena Cancer Center | South Pasadena | California | United States | 91030 |
3 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Seattle | Washington | United States | 98109 |
Sponsors and Collaborators
- City of Hope Medical Center
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Ravi Bhatia, MD, City of Hope Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 07203
- P30CA033572
- NOVARTIS-CSTI571AUS275T
- CDR0000596065
- NCI-2010-00528